Despite 150 years of availability of antituberculosis chemotherapy, tuberculosis remains a leading infectious cause of death worldwide, with 9 million new cases and nearly 2 million deaths annually [1] . Compounding the challenges of an already lengthy and complicated treatment course, the World Health Organization reported in 2008 the highest number of cases of drug-resistant tuberculosis to date. Isoniazid (INH) is an important first-lin agent for treatment of tuberculosis, because Control Section, for which 274 control subjects with drug-susceptible tuberculosis were selected as time-matched controls. The percentage of patients who completed treatment at the SFDPH Tuberculosis Control Section clinic was similar for both groups (87% vs. 83%;
), but P p .17 12-month follow-up after treatment was completed by a greater percentage of patients with INH-monoresistant tuberculosis, compared with patients with drug-susceptible tuberculosis (98% vs. 86%;
). P p .03 guideline recommending treatment with a standard 4-drug regimen (INH, rifampin, pyrazinamide, and ethambutol) for 6 months, with discontinuation of INH after the results of drugsusceptibility tests are known [4] . However, contemporary studies are still needed to better characterize risk factors for INH-monoresistant tuberculosis, as well as to evaluate the efficac of current treatment guidelines under program conditions.
To address these issues, we conducted a retrospective evaluation of tuberculosis cases reported to the San Francisco Department of Public Health (SFDPH) Tuberculosis Control Section. Our objectives were to determine risk factors for INH-monoresistant tuberculosis, to identify and describe the variations in treatment regimens for patients with INHmonoresistant tuberculosis, and to compare treatment outcomes for patients with INH-monoresistant tuberculosis with those for patients with drug-susceptible tuberculosis treated under program conditions.
METHODS
Study population and setting. The records of the SFDPH Tuberculosis Control Section were reviewed to identify all cases of culture-confi med, INH-monoresistant tuberculosis reported in San Francisco, California, from 1 October 1992 through 31 October 2005. Cases were excluded if INH resistance was acquired during treatment or if resistance to any other first-lin antituberculosis medication was documented. For each INH-monoresistant tuberculosis case identified the next 2 reported cases of drug-susceptible tuberculosis were selected to establish a time-matched comparison cohort. Drug-susceptible tuberculosis cases were required to have documented susceptibility to INH, rifampin, pyrazinamide, and ethambutol.
Study design. For both drug-susceptible and INH-monoresistant tuberculosis cases, demographic and clinical characteristics were extracted from the SFDPH Tuberculosis Control Section electronic database. In addition, medical charts were retrospectively reviewed using a standardized data-abstraction form to obtain detailed information on prior tuberculosis treatment, treatment regimens, adverse drug reactions, adherence to therapy, and clinical follow-up for 1 year after treatment completion. The study protocol was approved by the University of California, San Francisco, Committee on Human Research.
Definitions Drug susceptibility was confi med in all cases at the SFDPH laboratory by use of the agar-proportion method [5] . INH resistance was classifie as either low level or high level when there was 11% growth of Mycobacterium tuberculosis complex in the presence of 0.2 mg/mL or 1 mg/mL of INH, respectively. Treatment was considered completed if all antituberculosis chemotherapy had been administered and there was either microbiological confi mation of cure or an indication in the medical record that the patient had received an effective course of treatment. An adverse drug reaction was define as any symptom or laboratory abnormality leading to interruption of у1 antituberculosis medication. Patients were considered to have nonadherence to treatment if any of the following conditions were met: (1) 114 consecutive days of treatment were missed, (2) 12 consecutive visits to the clinic were missed, or (3) 120% of doses were missed in any month by a patient receiving directly observed therapy. The primary outcomes for the study were (1) a combined end point of treatment failure or relapse and (2) all-cause mortality while receiving tuberculosis treatment. In accordance with ATS/CDC/ IDSA guidelines, a patient was considered to have treatment failure if culture results remained positive after 4 months of treatment and to have had a relapse when a second episode of tuberculosis was diagnosed within 1 year after treatment completion [4] . IS6110 genotyping results were used to confir that the second episodes were true relapses rather than subsequent infections with new M. tuberculosis strains, as described elsewhere [6] .
Statistical analysis. Statistical analyses were performed using Stata, version 9.0 (Stata Corp.), with the level of signif cance specifie in reference to a 2-tailed, type I error (P value) of status) and outcome variables. Additional predictor variables were included in the model if either of the following criteria were met: (1) the predictor was associated with the outcome at the prespecifie significanc level of , or (2) the pre-P ! .05 dictor was associated with both the primary predictor and outcome variables at the prespecifie significanc level of . P ! .2 Cox proportional-hazards assumptions were tested using the method of Schoenfeld residuals, and the primary predictor (INH-resistance status) was determined to meet assumptions ( ). The c statistic was calculated as a standard summary P 1 .05 measure of model performance.
RESULTS

Study population.
During the study period, there were 137 cases of INH-monoresistant tuberculosis reported to the SFDPH Tuberculosis Control Section, for which 274 control subjects with drug-susceptible tuberculosis were selected as time-matched controls. Of the 137 patients with INH-monoresistant tuberculosis, 82 (60%) had high-level INH resistance. The percentage of patients who completed treatment at the SFDPH Tuberculosis Control Section clinic was similar for the group with drug-susceptible tuberculosis and the group with INH-monoresistant tuberculosis (87% vs. 83%;
) (fi -P p .17 ure 1). However, 1-year posttreatment follow-up was completed by a greater percentage of the group with INH-monoresistant tuberculosis (98% vs. 86%;
). P p .03 Demographic and clinical characteristics. In bivariate HREZ (2), REZ (5-7) 5 (4) HREZ (9) 3 (3) HRE (9-12) 2 (2) HREZ (2), RE (7) (8) (9) (10) 23 (19) HREZ (2), REZ (7-10) 11 (9) HREZ (2), HRE (7) (8) (9) (10) 4 (3) The clinical presentation of tuberculosis did not differ significantl between the 2 groups. The percentages of patients with fever, night sweats, weight loss, and hemoptysis were similar (all P values у.2; data not shown). The same percentage of patients in each group presented with extrapulmonary tuberculosis (12%). Factors associated with the extent of disease, such as positive results of acid-fast bacilli smear test (47% vs.
41%;
) and cavitation on initial chest radiograph (18% P p .29 vs. 14%; ), were not significantl different between the P p .26 group with INH-monoresistant tuberculosis and the group with drug-susceptible tuberculosis. There were, however, some differences in characteristics associated with treatment. Patients with INH-monoresistant tuberculosis received a longer duration of treatment (median, 306 vs. 220 days; ), were P ! .001 more likely to experience an adverse drug reaction requiring an interruption in therapy (31% vs. 15%; ), and were P ! .001 more likely to complete treatment at the SFDPH Tuberculosis Control Section clinic (82% vs. 65%; ). Of note, patients P ! .001 who received treatment at the SFDPH Tuberculosis Control Section clinic overall were less likely to have extrapulmonary tuberculosis (10% vs. 19%;
) and to die during tuber-P p .01 culosis treatment (5% vs. 16%;
) and were more likely P ! .001 to receive directly observed therapy (59% vs. 37%; ), P ! .001 compared with patients whose treatment was managed by nontuberculosis clinic providers.
Treatment regimens. Detailed treatment information was available for all 119 patients with INH-monoresistant tuberculosis who completed treatment. Overall, treatment was given daily in the continuation phase to 117 patients (98%) and was given twice weekly and 3 times weekly to 1 patient each. At least 6 months of treatment with rifampin were completed by 89% of patients, ethambutol by 87%, and pyrazinamide by 56%. INH was continued for 22 (18%) of the patients even after INH resistance was identified 17 (77%) of these 22 patients were infected with M. tuberculosis isolates displaying lowlevel INH resistance. A 6-month treatment regimen was completed by 49 (41%) of the 119 patients, 43 (88%) of whom received first-lin ATS/CDC/IDSA-recommended treatment (table 3) . Treatment was extended beyond 6 months for 70 patients (59%), of whom 53 (45%) completed a 7-12-month , by log-rank test). P ! .007 course of treatment and 17 (14%) completed a 112-month course. For patients who received extended treatment, 10 different regimens containing first-lin drugs and 18 different regimens containing second-line drugs were used (table 3) .
Treatment was extended beyond 6 months for 35 patients (29%) because pyrazinamide was discontinued in the continuation phase of treatment (table 4). For 17 patients (14%), all of whom received treatment before 1997, pyrazinamide was discontinued because of physician preference. Pyrazinamide was discontinued for another 16 patients (13%) during the continuation phase of treatment because of an adverse reaction; of these patients, 8 (7%) had hepatotoxicity. No demographic or clinical characteristics were associated with either pyrazinamide discontinuation or treatment extension beyond 6 months in either bivariate or multivariate analysis (data not shown).
Clinical outcomes. The combined end point of treatment failure or relapse occurred for only 2 (2%) of the patients with INH-monoresistant tuberculosis (both had relapses and both were receiving a daily regimen) and 5 (2%) of the patients with drug-susceptible tuberculosis (2 had relapses and 3 had treatment failures). The treatment regimens used for the 2 patients with INH-monoresistant tuberculosis who had relapses were as follows: INH, rifampin, pyrazinamide, and ethambutol for 2 months followed by rifampin, pyrazinamide, and ethambutol for 4 months for one patient and INH, rifampin, pyrazinamide, and ethambutol for 2 months followed by rifampin and ethambutol for 7-10 months for the other patient. There was no association between INH-resistance status and the combined end point of treatment failure or relapse (OR, 0.75; 95% CI, 0.14-3.92;
). Multivariate analysis was not performed P p 0.73 because of the small number of patients with this end point.
All-cause mortality during tuberculosis treatment was reported for 5 (4%) of the patients with INH-monoresistant tuberculosis and 30 (11%) of the patients with drug-susceptible tuberculosis. Among the group with INH-monoresistant tuberculosis, all-cause mortality was lower for patients with highlevel INH resistance than for patients with low-level INH resistance (2% vs. 6%; ), although this association was P p .30 not statistically significant In Kaplan-Meier survival analysis, survival was significantl greater for patients with INH-monoresistant tuberculosis, compared with patients with drug-susceptible tuberculosis ( ) (figu e 2). Only HIV status, P ! .007 results of sputum acid-fast bacilli smear examination, age, inhospital diagnosis of tuberculosis, and treatment location satisfie the prespecifie criteria for inclusion in a multivariate analysis of all-cause mortality. After adjustment for these factors, the association between INH monoresistance and decreased all-cause mortality (hazard ratio, 0.43; 95% CI, 0.16-1.13; ) (table 5) did not reach the prespecif ed threshold P p .09 for statistical signif cance.
DISCUSSION
In this study, we performed the largest comparison reported to date of clinical characteristics and treatment outcomes between patients with INH-monoresistant tuberculosis and patients with drug-susceptible tuberculosis under program con-ditions. We found that a history of treatment for latent or active tuberculosis was strongly associated with subsequent INH monoresistance. With regard to treatment outcomes, we found that both the ATS/CDC/IDSA-recommended 6-month treatment regimen (INH, rifampin, pyrazinamide, and ethambutol for 2 months followed by rifampin, pyrazinamide, and ethambutol for 4 months) and extended treatment regimens for INHmonoresistant tuberculosis were highly effective, resulting in only 2 cases of relapse. However, our finding suggest that new, short-course treatment regimens are needed, because at least 13% of patients were unable to tolerate pyrazinamide during the continuation phase of treatment.
Our multivariate analysis showed that prior tuberculosis treatment was the only risk factor significantl associated with INH monoresistance. Although previous studies have reported an association between prior treatment for active tuberculosis and INH monoresistance [7] [8] [9] [10] [11] , our analysis demonstrates that INH therapy for latent tuberculosis infection may also increase the risk of INH-resistant tuberculosis. This fi ding is in line with the results of a recent meta-analysis of trials of INH preventive therapy, in which the authors concluded that a significan association between INH preventive therapy and drug-resistant tuberculosis could not be excluded (relative risk, 1.45; 95% CI, 0.85-2.47) [12] .
Another findin of concern in our study was the poor tolerability of the first-lin ATS/CDC/IDSA-recommended treatment regimen for INH-monoresistant tuberculosis. This treatment regimen was discontinued for 13% of patients because of an adverse reaction to pyrazinamide, most commonly hepatotoxicity. We had limited statistical power to determine whether treatment with rifampin and pyrazinamide alone in the absence of INH [13] , use of pyrazinamide in the continuation phase [14] , or other factors were associated with the high proportion of pyrazinamide-related adverse events observed in our study. However, similar finding were reported for a cohort of mostly drug-susceptible tuberculosis cases in Montreal, Quebec, in which the incidence of major adverse reactions was at least 3 times higher with use of pyrazinamide, compared with use of INH, rifampin, and ethambutol [15] . Alternative short-course regimens that do not require extended use of pyrazinamide are clearly needed for treatment of INHmonoresistant tuberculosis.
An unanticipated findin of our study was the decreased allcause mortality during tuberculosis treatment among patients with INH-monoresistant tuberculosis, compared with that among patients with drug-susceptible tuberculosis. This fi ding should be interpreted with caution, because it failed to meet the prespecifie threshold for statistical significanc in multivariate analysis and because of the limitations inherent in a retrospective analysis. It is possible that the decreased all-cause mortality observed among the cohort with INH-monoresistant tuberculosis may be partly explained by differences between the case and control populations, such as the presence of comorbid medical conditions, the severity and extent of tuberculosis, and variations in clinical care, for which we were unable to adjust in our analyses. Nonetheless, there are biologically plausible explanations for a possible association between INH monoresistance and decreased virulence [16] [17] [18] [19] [20] [21] . Population-based studies have shown that M. tuberculosis strains harboring certain INH-resistance mutations, including a serine-to-threonine substitution at amino acid position 315 of katG, are less likely to generate secondary cases [22, 23] . Similar studies are needed to establish whether these or other mutations have an impact on M. tuberculosis virulence in addition to transmission.
In summary, our study identifie prior treatment for latent tuberculosis and prior treatment for active tuberculosis as independent risk factors for subsequent INH monoresistance. This troubling association with INH preventive therapy is in agreement with a recently published meta-analysis [12] and deserves further evaluation. With regard to tuberculosis treatment outcomes, our study offers additional evidence supporting the use of the daily, first-lin treatment regimen currently endorsed by the ATS/CDC/IDSA guidelines for INH-monoresistant tuberculosis [4] . However, the high incidence of drug toxicity suggests that new, short-course regimens are needed to combat the increasing numbers of INH-resistant tuberculosis cases worldwide. Lastly, the association identifie between INH monoresistance and decreased all-cause mortality is intriguing. The hypothesis that mutations conferring INH resistance may decrease M. tuberculosis virulence deserves further study.
